ArticleScientific reports2020
Forty-year prognosis after plaque brachytherapy of uveal melanoma.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Comparing efficacy of charged-particle therapy with brachytherapy in treatment of uveal melanoma.Eye (London, England) · 2024Pooled it
- Long-Term Local Control and Mortality After Transpupillary Thermotherapy of Small Uveal Melanomas.Clinical & experimental ophthalmology · 2026Article
- Deep Learning and Experimental Validation of BRCA1-Associated Protein-1 Missense Variant Pathogenicity in Uveal Melanoma.Ophthalmology science · 2026Article
- The optimal approach to the primary treatment of uveal melanoma: a narrative review.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2026Review
- Automatic classification of uveal melanoma response patterns following ruthenium-106 plaque brachytherapy using ultrasound images and deep convolutional neural network.Scientific reports · 2025Article
- Threshold analysis of mortality outcomes in the collaborative ocular melanoma study (COMS).Melanoma management · 2025Article
- Review
- Radiotherapy has a survival advantage over surgery in patients with choroidal melanoma: a retrospective cohort study of 6,871 patients.Frontiers in surgery · 2025Article
- Proton Therapy in Uveal Melanoma.Cancers · 2024Review
- Melatonin Receptor Expression in Primary Uveal Melanoma.International journal of molecular sciences · 2024Article
- Comprehensive causes of death in uveal melanoma: mortality in 1530 consecutively diagnosed patients followed until death.JNCI cancer spectrum · 2023Article
- The prognostic implication of visual acuity at the time of uveal melanoma diagnosis.Eye (London, England) · 2023Article
- An empirical approach to the definition of the target margins in eye radiosurgery.Journal of applied clinical medical physics · 2023Article
- A serum protein signature at the time of Uveal Melanoma diagnosis predicts long-term patient survival.BMC cancer · 2023Article
- The prognostic implication of latitude in uveal melanoma: a nationwide observational cohort study of all patients born in Sweden between 1947 and 1989.Discover oncology · 2022Article
- The rationale for treating uveal melanoma with adjuvant melatonin: a review of the literature.BMC cancer · 2022Review
- Vasculogenic mimicry correlates to presenting symptoms and mortality in uveal melanoma.Journal of cancer research and clinical oncology · 2022Article
- Radiological and clinical findings in uveal melanoma treated by plaque interventional radiotherapy (brachytherapy): Visual atlas and literature review on response assessment.Journal of contemporary brachytherapy · 2022Article
- The prognostic value of immune-related genesFrontiers in oncology · 2022Article
- Trends in Uveal Melanoma Presentation and Survival During Five Decades: A Nationwide Survey of 3898 Swedish Patients.Frontiers in medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, the long-term patient survival after plaque brachytherapy of uveal melanoma is examined. All patients treated between 1980 and 1999 at a single institution were included (n = 677). 533 (79%) had deceased before the end of follow-up. The median follow-up for the 144 survivors was 25.4 years (SD 5.2). Uveal melanoma-related mortality was 18% by 5 years, 28% by 10 years, 32% by 15 years, 35% by 20 years, and 36% by 25 to 40 years. 172 of 209 (82%) uveal melanoma-related deaths occurred within the first decade after brachytherapy. Relative survival rates were 74% at 5 years, 64% at 10 years, 62% at 20 years, 83% at 30 years and ≥100% at 32 to 40 years. Tumor diameter and local recurrence were independent predictors of uveal melanoma-related mortality in multivariate Cox proportional hazards analysis. In conclusion, uveal melanoma has a high mortality rate and most uveal melanoma-related deaths occur in the first decade after treatment. Long-term survivors may have a survival advantage to individuals of the same sex and age from the general population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.